Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGS-Guided Therapy vs Physician Discretion in Cancer
NCT02132845Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Mar 2016
- Primary completion
- May 2018
- Countries
- 1
01
Overview
Randomised, open-label trial in malignant neoplasm (2 arms), sponsored by Fox Chase Cancer Center. Primary endpoint: Overall (composite) response rate at 2 years. Started Mar 2016; status: completed.
02
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT02132845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02132845.